FTI-2153 is a potent and highly selective farnesyltransferase (FTase) inhibitor (IC50 = 1.4 nM) that effectively inhibits H-Ras protein processing (IC50 = 10 nM), with over 3000-fold selectivity over Rap1A processing. It inhibits bipolar spindle formation during mitosis independently of cellular transformation status and Ras or p53 mutation status in human lung cancer cell lines. FTI-2153 induces prometaphase arrest with ring-like or rosette-shaped chromosome morphology surrounding a monoaster of microtubules, and alters mitotic phase distribution by increasing prometaphase cells while decreasing telophase/cytokinesis cells in various cancer and non-transformed cell lines. It also demonstrates antiproliferative activity against multiple cancer cell lines, including T-24, Calu-1, A-549, and OVCAR3.